Data as of Nov 26
| +1.54 / +1.39%|
The 23 analysts offering 12-month price forecasts for Celgene have a median target of 115.00, with a high estimate of 136.00 and a low estimate of 66.00. The median estimate represents a +2.12% increase from the last price of 112.61.
The current consensus among 26 polled investment analysts is to Buy stock in Celgene. This rating has held steady since November, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.